Comparison Of King’s Clinical Staging In Multinational Amyotrophic Lateral Sclerosis Cohorts

References

• Talbot K. Motor neuron disease: the bare essentials. Pract Neurol. 2009;9:303–9.
   PubMedGoogle Scholar
• Canosa A, Calvo A, Moglia C, Manera U, Vasta R, Di Pede F, et al. Brain metabolic changes across King's stages in amyotrophic lateral sclerosis: a (18)F-2-fluoro-2-deoxy-D-glucose-positron emission tomography study. Eur J Nucl Med Mol Imaging. 2021;48:1124–33.
   PubMed Web of Science ®Google Scholar
• Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847–52.
   PubMed Web of Science ®Google Scholar
• Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw J, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry 2014;86:45–49.
   PubMed Web of Science ®Google Scholar
• Consonni M, Dalla Bella E, Contarino VE, Bersano E, Lauria G. Cortical thinning trajectories across disease stages and cognitive impairment in amyotrophic lateral sclerosis. Cortex. 2020;131:284–94.
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Han Y, Song Y, Gao Y. Correlational analysis of als progression and serum nfl measured by simoa assay in chinese patients. Front Neurol 2020;11:579094.
   PubMed Web of Science ®Google Scholar
• Abdul Aziz NA, Toh T-H, Loh E-C, Capelle DP, Goh K-J, Abdul Latif L, et al. The utility of ALS staging systems in a multi-ethnic patient cohort. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:341–9.
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Mori M, Liu J, Shibuya K, Isose S, Koide M, et al. Novel serum autoantibodies against ss-actin (ACTB) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener.2021;22:388–94.
   PubMed Web of Science ®Google Scholar
• Luna J, Couratier P, Lahmadi S, Lautrette G, Fontana A, Tortelli R, et al. Comparison of the ability of the King's and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:478–85.
   PubMed Web of Science ®Google Scholar
• Wei Q-Q, Hou Y, Chen Y, Ou R, Cao B, Zhang L, et al. Health-related quality of life in amyotrophic lateral sclerosis using EQ-5D-5L. Health Qual Life Outcomes. 2021;19:181.
   PubMedGoogle Scholar
• Devenney EM, McErlean K, Tse NY, Caga J, Dharmadasa T, Huynh W, et al. Factors that influence non-motor impairment across the ALS-FTD spectrum: impact of phenotype, sex, age, onset and disease stage. Front Neurol 2021;12:743688.
   PubMed Web of Science ®Google Scholar
• Floeter MK, Danielian LE, Braun LE, Wu T. Longitudinal diffusion imaging across the C9orf72 clinical spectrum. J Neurol Neurosurg Psychiatry. 2018;89:53–60.
   PubMed Web of Science ®Google Scholar
• Balendra R, Al Khleifat A, Fang T, Al-Chalabi A. A standard operating procedure for King’s ALS clinical staging. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:159–64.
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat A, Meurgey J-H, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416–22.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Chiò A, Merrill C, Oster G, Bornheimer R, Agnese W, et al. Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. J Neurol Neurosurg Psychiatry. 2021;92:165–71.
   PubMed Web of Science ®Google Scholar
• UKMND-LiCALS Study Group, Morrison KE, Dhariwal S, Hornabrook R, Savage L, Burn DJ, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:339–45.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Shaw PJ, Young CA, Morrison KE, Murphy C, Thornhill M, et al. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31]. BMC Neurol. 2011;11:111.
   PubMed Web of Science ®Google Scholar
• Phase A. 2–3 trial of olesoxime in subjects with amyotrophic lateral sclerosis, 23rd International Symposium on ALS/MND Abstracts. Amyotrophic Lateral Sclerosis 2012;13:1–58.
   Google Scholar
• Gomeni R, Fava M. Amyotrophic lateral sclerosis disease progression model. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:119–29.
   PubMed Web of Science ®Google Scholar
• Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:279–84.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Salachas F, Lacomblez L, Forestier NL, Pradat PF, Bruneteau G, et al. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience. Neuro-Degenerative Diseases 2012;12:81–90.
   PubMed Web of Science ®Google Scholar
• Bae JS, Hong Y-H, Baek W, Sohn EH, Cho J-Y, Kim B-J, et al. Current status of the diagnosis and management of amyotrophic lateral sclerosis in Korea: a multi-center cross-sectional study. J Clin Neurol. 2012;8:293–300.
   PubMed Web of Science ®Google Scholar
• Pradas J, Puig T, Rojas-García R, Viguera ML, Gich I, Logroscino G, et al. Amyotrophic lateral sclerosis in Catalonia: a population based study. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:278–83.
   PubMed Web of Science ®Google Scholar
• Khishchenko N, Allen KD, Coffman CJ, Kasarskis EJ, Lindquist JH, Morgenlander JC, et al. Time to diagnosis in the National Registry of Veterans with Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler. 2010;11:125–32.
   PubMed Web of Science ®Google Scholar
• Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002;59:280–2.
   PubMed Web of Science ®Google Scholar
• Bandettini di Poggio M, Sormani MP, Truffelli R, Mandich P, Origone P, Verdiani S, et al. Clinical epidemiology of ALS in Liguria, Italy. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:52–7.
   PubMed Web of Science ®Google Scholar
• Forbes RB, Colville S, Swingler RJ. The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over. Age Ageing. 2004;33:131–4.
   PubMed Web of Science ®Google Scholar
• Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:639–49.
   PubMed Web of Science ®Google Scholar
• Ganesalingam J, Stahl D, Wijesekera L, Galtrey C, Shaw CE, Leigh PN, et al. Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PloS One. 2009;4:e7107.
   PubMed Web of Science ®Google Scholar
• Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
   PubMed Web of Science ®Google Scholar
• Preux PM, Couratier P, Boutros-Toni F, Salle JY, Tabaraud F, Bernet-Bernady P, et al. Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors. Neuroepidemiology 1996;15:153–60.
   PubMed Web of Science ®Google Scholar
• Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A, et al. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders: official publication of the World Federation of Neurology. Research Group on Motor Neuron Diseases.2002;3:15–21.
   Google Scholar
• Higo R, Tayama N, Nito T. Longitudinal analysis of progression of dysphagia in amyotrophic lateral sclerosis. Auris Nasus Larynx. 2004;31:247–54. doi:
   PubMed Web of Science ®Google Scholar
• Montes J, Levy G, Albert S, Kaufmann P, Buchsbaum R, Gordon PH, et al. Development and evaluation of a self-administered version of the ALSFRS-R. Neurology 2006;67:1294–6. doi:
   PubMed Web of Science ®Google Scholar
• Montes J, Levy G, Richard B, Kaufmann P, Buchsbaum R, Gordon PH, et al. Development and evaluation of the ALSFRS-R as a self-administered tool in patients with ALS. Neurology 2006;66:A246–A46.
   Web of Science ®Google Scholar
• Maier A, Holm T, Wicks P, Steinfurth L, Linke P, Münch C, et al. Online assessment of ALS functional rating scale compares well to in-clinic evaluation: a prospective trial. Amyotrophic Lateral Sclerosis.2012;13:210–6. doi:
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Motor neurone disease: the use of non-invasive ventilation in the management of motor neurone disease. London: National Institute for Health and Clinical Excellence. 2010. Available at: www.nice.org.uk/guidance/NG42
   Google Scholar
• O’Neill CL, Williams TL, Peel ET, McDermott CJ, Shaw PJ, Gibson GJ, et al. Non-invasive ventilation in motor neuron disease: an update of current UK practice. J Neurol Neurosurg Psychiatry. 2012;83:371–6. doi:
   PubMed Web of Science ®Google Scholar
• Albert SM, Whitaker A, Rabkin JG, del Bene M, Tider T, O’Sullivan I, et al. Medical and supportive care among people with ALS in the months before death or tracheostomy. J Pain Symptom Manag.2009;38:546–53. doi:
   PubMed Web of Science ®Google Scholar
• Borasio CD, Gelinas DF, Yanagisawa N. Mechanical ventilation in amyotrophic lateral sclerosis: a cross-cultural perspective. J Neurol. 1998;245:S7–S12.
   PubMed Web of Science ®Google Scholar
• Melo J, Homma A, Iturriaga E, Frierson L, Amato A, Anzueto A, et al. Pulmonary evaluation and prevalence of non-invasive ventilation in patients with amyotrophic lateral sclerosis: a multicenter survey and proposal of a pulmonary protocol. J Neurol Sci. 1999;169:114–7. doi:
   PubMed Web of Science ®Google Scholar
• Borasio GD, Shaw PJ, Hardiman O, Ludolph AC, Sales Luis ML, Silani V, et al. Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:159–64. doi:
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Grp BS. Disease status and use of ventilatory support by ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:19–22.
   PubMed Web of Science ®Google Scholar
• Bradley WG, Anderson F, Gowda N, Miller RG. Changes in the management of ALS since the publication of the AAN ALS Practice Parameter 1999. Amyotroph Lateral Sc.2004;5:240–4. doi:
   PubMed Web of Science ®Google Scholar
• Georgoulopoulou E, Fini N, Vinceti M, Monelli M, Vacondio P, Bianconi G, et al. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.2013;14:338–45.
   PubMed Web of Science ®Google Scholar
• Vrijsen B, Testelmans D, Belge C, Robberecht W, Van Damme P, Buyse B, et al. Non-invasive ventilation in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.2013;14:85–95.
   PubMed Web of Science ®Google Scholar
• Gruis KL, Lechtzin N. Respiratory therapies for amyotrophic lateral sclerosis: a primer. Muscle Nerve. 2012;46:313–31.
   PubMed Web of Science ®Google Scholar
• Sivak ED, Shefner JM, Mitsumoto H, Taft JM. The use of non-invasive positive pressure ventilation (NIPPV) in ALS patients. A need for improved determination of intervention timing. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:139–45. doi:
   PubMed Web of Science ®Google Scholar
• Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosur Ps.2011;82:628–34. doi:
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1218–26.
   PubMed Web of Science ®Google Scholar
• Pena MJ, Ravasco P, Machado M, Pinto A, Pinto S, Rocha L, et al. What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis? Amyotrophic Lateral Sclerosis.2012;13:550–4. doi:
   PubMed Web of Science ®Google Scholar
• Hardiman O. Symptomatic treatment of respiratory and nutritional failure in amyotrophic lateral sclerosis. J Neurol. 2000;247:245–51. doi:
   PubMed Web of Science ®Google Scholar
• Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, et al. Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:285–91.
   PubMed Web of Science ®Google Scholar
• Oh J, An JW, Oh S-I, Oh KW, Kim JA, Lee JS, et al. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:202–8.
   PubMed Web of Science ®Google Scholar
• Moore A, Young CA, Hughes DA. Health utilities and costs for motor neurone disease. Value Health. 2019;22:1257–65.
   PubMed Web of Science ®Google Scholar
• Leigh PN, Abrahams S, Al-Chalabi A, et al. The management of motor neurone disease. Journal of Neurology, Neurosurgery, and Psychiatry 2003;74:iv32–iv47.
   PubMed Web of Science ®Google Scholar